TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT06855823

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Golicitinib combined with Pomadomide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Golicitinib combined with Pomadomide (DRUG): golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd

Drugs / treatments
Golicitinib combined with Pomadomide
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

NCT06855823

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is testing Golicitinib combined with Pomadomide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

Golicitinib combined with Pomadomide (DRUG): golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd

Drugs / treatments: Golicitinib combined with Pomadomide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 33 patients

Primary endpoint: Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) in Phase I; Objective Response Rate (ORR) in Phase II

Ages: 18 Years to 80 Years

Start date: 2025-01-14 | Est. completion: 2026-12

Locations

0 US sites · 1 total

Contact

Zhiming Li | lizhm@sysucc.org.cn | 86-020-87343009

Sponsor: Sun Yat-sen University (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06855823

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.